CTOs on the Move

454 Life Sciences, a Roche company

www.454.com

 
454 Life Sciences' system enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.454.com
  • 15 Commercial St
    Branford, CT USA 06405
  • Phone: 203.871.2300

Executives

Name Title Contact Details

Similar Companies

Predictive Biosciences

Predictive Biosciences is an innovative developer of molecular diagnostic tests for cancer diagnosis and monitoring. We are focused on understanding and meeting the needs of physicians by providing valuable diagnostic services and laboratory solutions.

BioVir Laboratories

BioVir Laboratories is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Horizon Agency Group

New Horizon Agency Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aderans Research Institute

Aderans Research Institute is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.